We invest in companies advancing science, developing new technologies, and changing how care is delivered. Our focus spans the discoveries, products, and systems that improve human health.
New tools for discovery.
Robotics and devices that act on real-world data.
Changing how people get care.
The systems healthcare runs on.
Preserving physical and cognitive function.
Practical support for building a company.
Our team includes physicians, scientists, founders, healthcare executives, and investors. We draw on that experience to help founders work through operating decisions, anticipate challenges, and connect with people who can help build the business.
1
We have an operator’s mindset and understand how to be of value. We ask critical questions, anticipate challenges before they arise, and ensure open dialogue every step of the way.
2
We’re forthright, open, and honest, even when it’s hard. And we expect the same from our partners.
3
We help our management teams make tangible progress. We ask the hard questions and always think about where the industry, company, and competition are going to ensure you’re positioned for lasting success.
4
Our data-driven market insights, focused network of experts, and real-world experience mean we know how to get things done for our partners and amplify their impact. We embrace the ambition of our partners and seek to make it a reality.
“Averin has been nothing short of spectacular. They are strategic, supportive, and bring a wealth of operational knowledge to the boardroom. Whether it’s sales strategy, key investor introductions, or talking through high-stakes partnership dynamics, you know you can trust their perspectives because they’ve been in your seat.”
Less documentation could mean longer patient conversations, more appointments, or lower staffing costs. Those are very different outcomes. Incentives decide where the saved time goes, and founders need to know who captures its value.
Read the articleIn Truth Rather Than Belief, David Berry explores how scientific consensus can limit innovation and why challenging established assumptions, following the data, and embracing unconventional ideas are essential to breakthrough discoveries.
Read the articleWhat if the cost of developing a medicine no longer determined which diseases get treated? The Case for Drug Abundance explores how advances in AI, human biology, automation, clinical development, and data could dramatically expand the num…
Read the articleWe built a system that pays for fifteen-minute encounters with people who are already sick. The annual visit gives you a level, never a trajectory. Here’s why the next decade replaces it with continuous observation, a 5x panel, and a physi…
Read the articleWhat live job postings reveal about the real gap, and what any team can do about it
Read the articleClinical AI is finally good enough to matter — but the real gating factor is not how impressive the accuracy metrics look on paper, it is underwriting. Whoever is willing to stand behind clinical AI with a clear medical malpractice and pro…
Read the articleThere is subtle but important shift in experimental medicine: states are no longer just reacting to the federal approval system, they are beginning to build parallel access regimes around unapproved treatments. Using Florida, Montana, and …
Read the articleThe next era of surgery will not be defined by robots alone, but by integrated systems of AI, visualization, and precision tools that expand what surgeons can do.
Read the article
